{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T03:35:15Z","timestamp":1784432115466,"version":"3.55.0"},"reference-count":117,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s13300-025-01761-4","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T04:23:35Z","timestamp":1749788615000},"page":"1557-1579","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Type\u00a02 Diabetes Mellitus Remission, Dream or Reality? A Narrative Review of Current Evidence and Integrated Care Strategies"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5621-1374","authenticated-orcid":false,"given":"Salvatore","family":"Corrao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Falcone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Mirarchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Amodeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,13]]},"reference":[{"issue":"10","key":"1761_CR1","doi-asserted-by":"publisher","first-page":"e1003396","DOI":"10.1371\/journal.pmed.1003396","volume":"17","author":"M Captieux","year":"2020","unstructured":"Captieux M, Prigge R, Wild S, Guthrie B. Defining remission of type\u00a02 diabetes in research studies: a systematic scoping review. PLoS Med. 2020;17(10):e1003396.","journal-title":"PLoS Med"},{"issue":"Supplement_1","key":"1761_CR2","doi-asserted-by":"publisher","first-page":"S179","DOI":"10.2337\/dc24-S010","volume":"47","author":"NA ElSayed","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee, ElSayed NA, Aleppo G, et al. 10. Cardiovascular disease and risk management: standards of care in diabetes\u20142024. Diabetes Care. 2024;47(Supplement_1):S179-218.","journal-title":"Diabetes Care"},{"issue":"Supplement_1","key":"1761_CR3","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.2337\/dc24-S001","volume":"47","author":"NA ElSayed","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee, ElSayed NA, Aleppo G, et al. 1. Improving care and promoting health in populations: standards of care in diabetes\u20142024. Diabetes Care. 2024;47(Supplement_1):S11\u20139.","journal-title":"Diabetes Care"},{"issue":"10","key":"1761_CR4","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.2337\/dbi20-0001","volume":"69","author":"E Ahlqvist","year":"2020","unstructured":"Ahlqvist E, Prasad RB, Groop L. Subtypes of type\u00a02 diabetes determined from clinical parameters. Diabetes. 2020;69(10):2086\u201393.","journal-title":"Diabetes"},{"issue":"5","key":"1761_CR5","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1210\/jc.2016-3373","volume":"102","author":"N McInnes","year":"2017","unstructured":"McInnes N, Smith A, Otto R, et al. Piloting a remission strategy in type\u00a02 diabetes: results of a randomized controlled trial. J Clin Endocrinol Metab. 2017;102(5):1596\u2013605.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"1761_CR6","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/S2213-8587(13)70006-8","volume":"1","author":"CK Kramer","year":"2013","unstructured":"Kramer CK, Zinman B, Retnakaran R. Short-term intensive insulin therapy in type\u00a02 diabetes mellitus: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2013;1(1):28\u201334.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"1761_CR7","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1111\/dom.15234","volume":"25","author":"N McInnes","year":"2023","unstructured":"McInnes N, Hall S, Lochnan HA, et al. Diabetes remission and relapse following an intensive metabolic intervention combining insulin glargine\/lixisenatide, metformin and lifestyle approaches: results of a randomised controlled trial. Diabetes Obes Metab. 2023;25(11):3347\u201355.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"1761_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2016-000270","volume":"4","author":"CK Kramer","year":"2016","unstructured":"Kramer CK, Zinman B, Choi H, Retnakaran R. Predictors of sustained drug-free diabetes remission over 48\u00a0weeks following short-term intensive insulin therapy in early type\u00a02 diabetes. BMJ Open Diab Res Care. 2016;4(1):e000270.","journal-title":"BMJ Open Diab Res Care"},{"key":"1761_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.107040","volume":"199","author":"ME Lunati","year":"2024","unstructured":"Lunati ME, Cimino V, Bernasconi D, et al. Type\u00a02 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide. Pharmacol Res. 2024;199:107040.","journal-title":"Pharmacol Res"},{"issue":"10","key":"1761_CR10","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.2337\/dci21-0034","volume":"44","author":"MC Riddle","year":"2021","unstructured":"Riddle MC, Cefalu WT, Evans PH, et al. Consensus report: definition and interpretation of remission in type\u00a02 diabetes. Diabetes Care. 2021;44(10):2438\u201344.","journal-title":"Diabetes Care"},{"issue":"11","key":"1761_CR11","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.2337\/dc09-9036","volume":"32","author":"JB Buse","year":"2009","unstructured":"Buse JB, Caprio S, Cefalu WT, et al. How do we define cure of diabetes? Diabetes Care. 2009;32(11):2133\u20135.","journal-title":"Diabetes Care"},{"issue":"1","key":"1761_CR12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12902-023-01283-9","volume":"23","author":"X Zhou","year":"2023","unstructured":"Zhou X, Zeng C. Diabetes remission of bariatric surgery and nonsurgical treatments in type\u00a02 diabetes patients who failure to meet the criteria for surgery: a systematic review and meta-analysis. BMC Endocr Disord. 2023;23(1):46.","journal-title":"BMC Endocr Disord"},{"issue":"1","key":"1761_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1517\/14796678.1.1.39","volume":"1","author":"H Bays","year":"2005","unstructured":"Bays H, Abate N, Chandalia M. Adiposopathy: sick fat causes high blood sugar, high blood pressure and dyslipidemia. Future Cardiol. 2005;1(1):39\u201359.","journal-title":"Future Cardiol"},{"issue":"11","key":"1761_CR14","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1161\/CIRCRESAHA.119.315896","volume":"126","author":"H Wu","year":"2020","unstructured":"Wu H, Ballantyne CM. Metabolic inflammation and insulin resistance in obesity. Circ Res. 2020;126(11):1549\u201364.","journal-title":"Circ Res"},{"issue":"4","key":"1761_CR15","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1152\/physrev.00030.2020","volume":"101","author":"J Ren","year":"2021","unstructured":"Ren J, Wu NN, Wang S, Sowers JR, Zhang Y. Obesity cardiomyopathy: evidence, mechanisms, and therapeutic implications. Physiol Rev. 2021;101(4):1745\u2013807.","journal-title":"Physiol Rev"},{"key":"1761_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2016.00157\/full","author":"I Ray","year":"2016","unstructured":"Ray I, Mahata SK, De RK. Obesity: an immunometabolic perspective. Front Endocrinol. 2016. https:\/\/doi.org\/10.3389\/fendo.2016.00157\/full.","journal-title":"Front Endocrinol"},{"key":"1761_CR17","doi-asserted-by":"publisher","unstructured":"Engin AB, Engin A, editors. The pathogenesis of obesity-associated adipose tissue inflammation. 2017;960. https:\/\/doi.org\/10.1007\/978-3-319-48382-5","DOI":"10.1007\/978-3-319-48382-5"},{"issue":"9","key":"1761_CR18","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1038\/oby.2011.32","volume":"20","author":"DD McManus","year":"2012","unstructured":"McManus DD, Lyass A, Ingelsson E, et al. Relations of circulating resistin and adiponectin and cardiac structure and function: the Framingham offspring study. Obesity. 2012;20(9):1882\u20136.","journal-title":"Obesity"},{"issue":"2","key":"1761_CR19","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.yjmcc.2008.05.006","volume":"45","author":"M Kim","year":"2008","unstructured":"Kim M, Oh JK, Sakata S, et al. Role of resistin in cardiac contractility and hypertrophy. J Mol Cell Cardiol. 2008;45(2):270\u201380.","journal-title":"J Mol Cell Cardiol"},{"issue":"6","key":"1761_CR20","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.cmet.2015.09.013","volume":"22","author":"Y Zhou","year":"2015","unstructured":"Zhou Y, Yu X, Chen H, et al. Leptin deficiency shifts mast cells toward anti-inflammatory actions and protects mice from obesity and diabetes by polarizing M2 macrophages. Cell Metab. 2015;22(6):1045\u201358.","journal-title":"Cell Metab"},{"issue":"12","key":"1761_CR21","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1056\/NEJMra1011035","volume":"371","author":"GI Shulman","year":"2014","unstructured":"Shulman GI. Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N Engl J Med. 2014;371(12):1131\u201341.","journal-title":"N Engl J Med"},{"key":"1761_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/175245","volume":"2012","author":"T Di Chiara","year":"2012","unstructured":"Di Chiara T, Argano C, Corrao S, Scaglione R, Licata G. Hypoadiponectinemia: a link between visceral obesity and metabolic syndrome. J Nutr Metab. 2012;2012:1\u20137.","journal-title":"J Nutr Metab"},{"issue":"5","key":"1761_CR23","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1111\/dom.15467","volume":"26","author":"S Corrao","year":"2024","unstructured":"Corrao S, Calvo L, Amico S, Argano C. The critical role of abdominal obesity as a crucial cardiovascular risk factor. Diabetes Obes Metab. 2024;26(5):1967\u201370.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"1761_CR24","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/nrendo.2015.25","volume":"11","author":"P Arner","year":"2015","unstructured":"Arner P, Kulyt\u00e9 A. MicroRNA regulatory networks in human adipose tissue and obesity. Nat Rev Endocrinol. 2015;11(5):276\u201388.","journal-title":"Nat Rev Endocrinol"},{"issue":"9","key":"1761_CR25","doi-asserted-by":"publisher","first-page":"773","DOI":"10.3389\/fendo.2018.00773","volume":"4","author":"SL Atkin","year":"2019","unstructured":"Atkin SL, Ramachandran V, Yousri NA, et al. Changes in blood microRNA expression and early metabolic responsiveness 21\u00a0days following bariatric surgery. Front Endocrinol. 2019;4(9):773.","journal-title":"Front Endocrinol"},{"issue":"1","key":"1761_CR26","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41577-019-0198-4","volume":"20","author":"H Tilg","year":"2020","unstructured":"Tilg H, Zmora N, Adolph TE, Elinav E. The intestinal microbiota fuelling metabolic inflammation. Nat Rev Immunol. 2020;20(1):40\u201354.","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"1761_CR27","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41574-019-0156-z","volume":"15","author":"EE Canfora","year":"2019","unstructured":"Canfora EE, Meex RCR, Venema K, Blaak EE. Gut microbial metabolites in obesity, NAFLD and T2DM. Nat Rev Endocrinol. 2019;15(5):261\u201373.","journal-title":"Nat Rev Endocrinol"},{"issue":"15","key":"1761_CR28","doi-asserted-by":"publisher","first-page":"1486793","DOI":"10.3389\/fendo.2024.1486793","volume":"17","author":"S Chong","year":"2025","unstructured":"Chong S, Lin M, Chong D, Jensen S, Lau NS. A systematic review on gut microbiota in type\u00a02 diabetes mellitus. Front Endocrinol. 2025;17(15):1486793.","journal-title":"Front Endocrinol"},{"issue":"4","key":"1761_CR29","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1056\/NEJMra2402679","volume":"392","author":"A Fasano","year":"2025","unstructured":"Fasano A. The physiology of hunger. N Engl J Med. 2025;392(4):372\u201381.","journal-title":"N Engl J Med"},{"issue":"9","key":"1761_CR30","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.1007\/s11695-020-04684-0","volume":"30","author":"N Davies","year":"2020","unstructured":"Davies N, O\u2019Sullivan JM, Plank LD, Murphy R. Gut microbial predictors of type\u00a02 diabetes remission following bariatric surgery. Obes Surg. 2020;30(9):3536\u201348.","journal-title":"Obes Surg"},{"key":"1761_CR31","doi-asserted-by":"publisher","unstructured":"Kinoshita K, Ozato N, Yamaguchi T, et al. Association of the gut microbiota with type\u00a02 diabetes: links to disease and remission in the Japanese population. 2025. J Diabetes Investig. https:\/\/doi.org\/10.1111\/jdi.70061.","DOI":"10.1111\/jdi.70061"},{"issue":"14","key":"1761_CR32","doi-asserted-by":"publisher","first-page":"1181744","DOI":"10.3389\/fendo.2023.1181744","volume":"17","author":"L Hern\u00e1ndez-Montoliu","year":"2023","unstructured":"Hern\u00e1ndez-Montoliu L, Rodr\u00edguez-Pe\u00f1a MM, Puig R, et al. A specific gut microbiota signature is associated with an enhanced GLP-1 and GLP-2 secretion and improved metabolic control in patients with type\u00a02 diabetes after metabolic Roux-en-Y gastric bypass. Front Endocrinol. 2023;17(14):1181744.","journal-title":"Front Endocrinol"},{"issue":"5","key":"1761_CR33","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s11883-014-0409-1","volume":"16","author":"H Bays","year":"2014","unstructured":"Bays H. Adiposopathy, \u201csick fat\u201d, Ockham\u2019s razor, and resolution of the obesity paradox. Curr Atheroscler Rep. 2014;16(5):409.","journal-title":"Curr Atheroscler Rep"},{"issue":"1","key":"1761_CR34","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12916-014-0123-4","volume":"12","author":"N Sattar","year":"2014","unstructured":"Sattar N, Gill JM. Type\u00a02 diabetes as a disease of ectopic fat? BMC Med. 2014;12(1):123.","journal-title":"BMC Med"},{"issue":"10","key":"1761_CR35","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1007\/s00125-011-2204-7","volume":"54","author":"EL Lim","year":"2011","unstructured":"Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R. Reversal of type\u00a02 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia. 2011;54(10):2506\u201314.","journal-title":"Diabetologia"},{"issue":"1","key":"1761_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2014-000079","volume":"3","author":"A Soare","year":"2015","unstructured":"Soare A, Del Toro R, Roncella E, et al. The effect of macrobiotic Ma-Pi 2 diet on systemic inflammation in patients with type\u00a02 diabetes: a post hoc analysis of the MADIAB trial. BMJ Open Diab Res Care. 2015;3(1):e000079.","journal-title":"BMJ Open Diab Res Care"},{"issue":"6","key":"1761_CR37","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S2213-8587(20)30117-0","volume":"8","author":"S Taheri","year":"2020","unstructured":"Taheri S, Zaghloul H, Chagoury O, , et al. Effect of intensive lifestyle intervention on bodyweight and glycaemia in early type\u00a02 diabetes (DIADEM-I): an open-label, parallel-group, randomised controlled trial. Lancet Diabetes Endocrinol. 2020;8(6):477\u201389.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"1761_CR38","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S2213-8587(23)00385-6","volume":"12","author":"ME Lean","year":"2024","unstructured":"Lean ME, Leslie WS, Barnes AC, et al. 5-year follow-up of the randomised diabetes remission clinical trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study. Lancet Diabetes Endocrinol. 2024;12(4):233\u201346.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"1761_CR39","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S2213-8587(19)30068-3","volume":"7","author":"MEJ Lean","year":"2019","unstructured":"Lean MEJ, Leslie WS, Barnes AC, et al. Durability of a primary care-led weight-management intervention for remission of type\u00a02 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol. 2019;7(5):344\u201355.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"23","key":"1761_CR40","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1001\/jama.2012.67929","volume":"308","author":"EW Gregg","year":"2012","unstructured":"Gregg EW, Chen H, Wagenknecht LE, et al. Association of an intensive lifestyle intervention with remission of type\u00a02 diabetes. JAMA. 2012;308(23):2489.","journal-title":"JAMA"},{"issue":"6","key":"1761_CR41","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1210\/clinem\/dgac661","volume":"108","author":"X Yang","year":"2023","unstructured":"Yang X, Zhou J, Shao H, et al. Effect of an intermittent calorie-restricted diet on type\u00a02 diabetes remission: a randomized controlled trial. J Clin Endocrinol Metab. 2023;108(6):1415\u201324.","journal-title":"J Clin Endocrinol Metab"},{"issue":"22","key":"1761_CR42","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type\u00a02 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"4","key":"1761_CR43","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type\u00a02 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"19","key":"1761_CR44","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type\u00a02 diabetes. N Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"issue":"7","key":"1761_CR45","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type\u00a02 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"10193","key":"1761_CR46","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type\u00a02 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121\u201330.","journal-title":"Lancet"},{"issue":"10295","key":"1761_CR47","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","volume":"398","author":"J Rosenstock","year":"2021","unstructured":"Rosenstock J, Wysham C, Fr\u00edas JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type\u00a02 diabetes (SURPASS-1): a double-blind, randomised, phase\u00a03 trial. Lancet. 2021;398(10295):143\u201355.","journal-title":"Lancet"},{"issue":"8","key":"1761_CR48","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1210\/clinem\/dgaa248","volume":"105","author":"N McInnes","year":"2020","unstructured":"McInnes N, Hall S, Sultan F, et al. Remission of type\u00a02 diabetes following a short-term intervention with insulin glargine, metformin, and dapagliflozin. J Clin Endocrinol Metab. 2020;105(8):2532\u201340.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9626","key":"1761_CR49","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/S0140-6736(08)60762-X","volume":"371","author":"J Weng","year":"2008","unstructured":"Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on \u03b2-cell function and glycaemic control in patients with newly diagnosed type\u00a02 diabetes: a multicentre randomised parallel-group trial. Lancet. 2008;371(9626):1753\u201360.","journal-title":"Lancet"},{"issue":"15","key":"1761_CR50","doi-asserted-by":"publisher","first-page":"1402583","DOI":"10.3389\/fendo.2024.1402583","volume":"24","author":"S Corrao","year":"2024","unstructured":"Corrao S, Pollicino C, Maggio D, Torres A, Argano C. Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence. Front Endocrinol. 2024;24(15):1402583.","journal-title":"Front Endocrinol"},{"key":"1761_CR51","doi-asserted-by":"crossref","unstructured":"Jastreboff AM, Le Roux CW, Stefanski A, et al. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med. 2025;392(10):958\u201371.","DOI":"10.1056\/NEJMoa2410819"},{"issue":"8","key":"1761_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2024.108800","volume":"38","author":"DS Popovic","year":"2024","unstructured":"Popovic DS, Patoulias D, Koufakis T, et al. Achievement of normoglycemia with tirzepatide in type\u00a02 diabetes mellitus: a step closer to drug-induced diabetes remission? J Diabetes Complications. 2024;38(8):108800.","journal-title":"J Diabetes Complications"},{"issue":"6","key":"1761_CR53","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type\u00a02 diabetes. N Engl J Med. 2021;385(6):503\u201315.","journal-title":"N Engl J Med"},{"issue":"8","key":"1761_CR54","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1111\/dom.14725","volume":"24","author":"JPH Wilding","year":"2022","unstructured":"Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553\u201364.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"1761_CR55","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1001\/jama.2023.24945","volume":"331","author":"LJ Aronne","year":"2024","unstructured":"Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38\u201348.","journal-title":"JAMA"},{"issue":"5","key":"1761_CR56","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s13300-024-01566-x","volume":"15","author":"RM Gutgesell","year":"2024","unstructured":"Gutgesell RM, Nogueiras R, Tsch\u00f6p MH, M\u00fcller TD. Dual and triple incretin-based co-agonists: novel therapeutics for obesity and diabetes. Diabetes Ther. 2024;15(5):1069\u201384.","journal-title":"Diabetes Ther"},{"issue":"Supplement_1","key":"1761_CR57","doi-asserted-by":"publisher","first-page":"1866-LB","DOI":"10.2337\/db24-1866-LB","volume":"73","author":"H Jiang","year":"2024","unstructured":"Jiang H, Ji L, Zhang Y, et al. 1866-LB: a phase\u00a02 study of mazdutide 9\u00a0mg in Chinese adults with BMI of 30 kg\/m2 or more. Diabetes. 2024;73(Supplement_1):1866-LB.","journal-title":"Diabetes"},{"issue":"3","key":"1761_CR58","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1210\/clinem\/dgz047","volume":"105","author":"VER Parker","year":"2020","unstructured":"Parker VER, Robertson D, Wang T, et al. Efficacy, safety, and mechanistic insights of cotadutide, a dual receptor glucagon-like peptide-1 and glucagon agonist. J Clin Endocrinol Metab. 2020;105(3):803\u201320.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1761_CR59","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa2301972","volume":"389","author":"AM Jastreboff","year":"2023","unstructured":"Jastreboff AM, Kaplan LM, Fr\u00edas JP, et al. Triple\u2013hormone-receptor agonist retatrutide for obesity\u2014a phase\u00a02 trial. N Engl J Med. 2023;389(6):514\u201326.","journal-title":"N Engl J Med"},{"issue":"1","key":"1761_CR60","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/dom.13494","volume":"21","author":"J Tillner","year":"2019","unstructured":"Tillner J, Posch MG, Wagner F, et al. A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: results of randomized, placebo-controlled first-in-human and first-in-patient trials. Diabetes Obes Metab. 2019;21(1):120\u20138.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"1761_CR61","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.2337\/dc20-2151","volume":"44","author":"R Nahra","year":"2021","unstructured":"Nahra R, Wang T, Gadde KM, et al. Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type\u00a02 diabetes: a 54-week randomized phase\u00a02b study. Diabetes Care. 2021;44(6):1433\u201342.","journal-title":"Diabetes Care"},{"issue":"5","key":"1761_CR62","first-page":"776","volume":"37","author":"M Samuel","year":"2021","unstructured":"Samuel M, Tardif JC, Bouabdallaoui N, et al. Colchicine for secondary prevention of cardiovascular disease: a systematic review and meta-analysis of randomized controlled trials. Can J Cardiol. 2021;37(5):776\u201385.","journal-title":"Can J Cardiol"},{"issue":"12","key":"1761_CR63","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119\u201331.","journal-title":"N Engl J Med"},{"key":"1761_CR64","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.trsl.2022.03.008","volume":"247","author":"GE Grieco","year":"2022","unstructured":"Grieco GE, Besharat ZM, Licata G, et al. Circulating microRNAs as clinically useful biomarkers for type\u00a02 diabetes mellitus: miRNomics from bench to bedside. Transl Res. 2022;247:137\u201357.","journal-title":"Transl Res"},{"issue":"3","key":"1761_CR65","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3390\/medicina59030636","volume":"59","author":"A Mauro","year":"2023","unstructured":"Mauro A, Lusetti F, Scalvini D, et al. A comprehensive review on bariatric endoscopy: where we are now and where we are going. Medicina. 2023;59(3):636.","journal-title":"Medicina"},{"issue":"9","key":"1761_CR66","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1001\/jama.2020.12567","volume":"324","author":"DE Arterburn","year":"2020","unstructured":"Arterburn DE, Telem DA, Kushner RF, Courcoulas AP. Benefits and risks of bariatric surgery in adults: a review. JAMA. 2020;324(9):879.","journal-title":"JAMA"},{"issue":"11","key":"1761_CR67","doi-asserted-by":"publisher","first-page":"741","DOI":"10.7326\/M17-2786","volume":"169","author":"D Arterburn","year":"2018","unstructured":"Arterburn D, Wellman R, Emiliano A, et al. Comparative effectiveness and safety of bariatric procedures for weight loss: a PCORnet cohort study. Ann Intern Med. 2018;169(11):741.","journal-title":"Ann Intern Med"},{"issue":"2","key":"1761_CR68","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s11695-017-2845-9","volume":"28","author":"R Welbourn","year":"2018","unstructured":"Welbourn R, Pournaras DJ, Dixon J, et al. Bariatric surgery worldwide: baseline demographic description and one-year outcomes from the second IFSO global registry report 2013\u20132015. Obes Surg. 2018;28(2):313\u201322.","journal-title":"Obes Surg"},{"issue":"17","key":"1761_CR69","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa1200111","volume":"366","author":"G Mingrone","year":"2012","unstructured":"Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type\u00a02 diabetes. N Engl J Med. 2012;366(17):1577\u201385.","journal-title":"N Engl J Med"},{"issue":"10271","key":"1761_CR70","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(20)32649-0","volume":"397","author":"G Mingrone","year":"2021","unstructured":"Mingrone G, Panunzi S, De Gaetano A, et al. Metabolic surgery versus conventional medical therapy in patients with type\u00a02 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2021;397(10271):293\u2013304.","journal-title":"Lancet"},{"issue":"8","key":"1761_CR71","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1007\/s11695-020-04644-8","volume":"30","author":"S Singh","year":"2020","unstructured":"Singh S, De Moura DTH, Khan A, et al. Intragastric balloon versus endoscopic sleeve gastroplasty for the treatment of obesity: a systematic review and meta-analysis. Obes Surg. 2020;30(8):3010\u201329.","journal-title":"Obes Surg"},{"issue":"11","key":"1761_CR72","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.3390\/biom11111582","volume":"11","author":"Y Ji","year":"2021","unstructured":"Ji Y, Lee H, Kaura S, et al. Effect of bariatric surgery on metabolic diseases and underlying mechanisms. Biomolecules. 2021;11(11):1582.","journal-title":"Biomolecules"},{"issue":"7","key":"1761_CR73","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.2337\/dc12-1535","volume":"36","author":"A Jim\u00e9nez","year":"2013","unstructured":"Jim\u00e9nez A, Casamitjana R, Viaplana-Masclans J, Lacy A, Vidal J. GLP-1 action and glucose tolerance in subjects with remission of type\u00a02 diabetes after gastric bypass surgery. Diabetes Care. 2013;36(7):2062\u20139.","journal-title":"Diabetes Care"},{"issue":"10","key":"1761_CR74","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.2337\/db14-0357","volume":"63","author":"A Jim\u00e9nez","year":"2014","unstructured":"Jim\u00e9nez A, Mari A, Casamitjana R, Lacy A, Ferrannini E, Vidal J. GLP-1 and glucose tolerance after sleeve gastrectomy in morbidly obese subjects with type\u00a02 diabetes. Diabetes. 2014;63(10):3372\u20137.","journal-title":"Diabetes"},{"issue":"6","key":"1761_CR75","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1530\/EJE-17-0446","volume":"177","author":"G Tharakan","year":"2017","unstructured":"Tharakan G, Behary P, Wewer Albrechtsen NJ, et al. Roles of increased glycaemic variability, GLP-1 and glucagon in hypoglycaemia after Roux-en-Y gastric bypass. Eur J Endocrinol. 2017;177(6):455\u201364.","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"1761_CR76","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1210\/en.2011-0281","volume":"152","author":"FM Fisher","year":"2011","unstructured":"Fisher FM, Estall JL, Adams AC, et al. Integrated regulation of hepatic metabolism by fibroblast growth factor\u00a021 (FGF21) in vivo. Endocrinology. 2011;152(8):2996\u20133004.","journal-title":"Endocrinology"},{"issue":"6","key":"1761_CR77","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/tpj.2012.43","volume":"13","author":"J Graessler","year":"2013","unstructured":"Graessler J, Qin Y, Zhong H, et al. Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type\u00a02 diabetes: correlation with inflammatory and metabolic parameters. Pharmacogenomics J. 2013;13(6):514\u201322.","journal-title":"Pharmacogenomics J"},{"issue":"7499","key":"1761_CR78","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nature13135","volume":"509","author":"KK Ryan","year":"2014","unstructured":"Ryan KK, Tremaroli V, Clemmensen C, et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature. 2014;509(7499):183\u20138.","journal-title":"Nature"},{"issue":"5","key":"1761_CR79","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.cmet.2019.03.009","volume":"29","author":"C Ling","year":"2019","unstructured":"Ling C, R\u00f6nn T. Epigenetics in human obesity and type\u00a02 diabetes. Cell Metab. 2019;29(5):1028\u201344.","journal-title":"Cell Metab"},{"issue":"4","key":"1761_CR80","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.giec.2024.03.004","volume":"34","author":"K Gala","year":"2024","unstructured":"Gala K, Ghusn W, Acosta A. Precision medicine in bariatric procedures. Gastrointest Endosc Clin N Am. 2024;34(4):765\u201379.","journal-title":"Gastrointest Endosc Clin N Am"},{"key":"1761_CR81","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-023-06048-6","author":"EW Gregg","year":"2024","unstructured":"Gregg EW, Chen H, Bancks MP, et al. Impact of remission from type\u00a02 diabetes on long-term health outcomes: findings from the Look AHEAD study. Diabetologia. 2024. https:\/\/doi.org\/10.1007\/s00125-023-06048-6.","journal-title":"Diabetologia"},{"key":"1761_CR82","doi-asserted-by":"crossref","unstructured":"Corrao S, Calvo L, Gran\u00e0 W, et al. Metabolic dysfunction-associated steatotic liver disease: A pathophysiology and clinical framework to face the present and the future. Nutr Metab Cardiovasc Dis. 2025;35(2):103702.","DOI":"10.1016\/j.numecd.2024.07.019"},{"issue":"10390","key":"1761_CR83","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1016\/S0140-6736(23)00634-7","volume":"401","author":"O Verrastro","year":"2023","unstructured":"Verrastro O, Panunzi S, Castagneto-Gissey L, et al. Bariatric\u2013metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial. Lancet. 2023;401(10390):1786\u201397.","journal-title":"Lancet"},{"key":"1761_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2024.111651","volume":"211","author":"G Mingrone","year":"2024","unstructured":"Mingrone G, Rajagopalan H. Bariatrics and endoscopic therapies for the treatment of metabolic disease: past, present, and future. Diabetes Res Clin Pract. 2024;211:111651.","journal-title":"Diabetes Res Clin Pract"},{"issue":"15","key":"1761_CR85","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","volume":"359","author":"RR Holman","year":"2008","unstructured":"Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type\u00a02 diabetes. N Engl J Med. 2008;359(15):1577\u201389.","journal-title":"N Engl J Med"},{"issue":"9","key":"1761_CR86","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1111\/dme.12727","volume":"32","author":"R Murphy","year":"2015","unstructured":"Murphy R, Jiang Y, Booth M, et al. Progression of diabetic retinopathy after bariatric surgery. Diabet Med. 2015;32(9):1212\u201320.","journal-title":"Diabet Med"},{"issue":"5\u20136","key":"1761_CR87","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.vph.2012.05.005","volume":"57","author":"A Ceriello","year":"2012","unstructured":"Ceriello A. The emerging challenge in diabetes: the \u201cmetabolic memory.\u201d Vascul Pharmacol. 2012;57(5\u20136):133\u20138.","journal-title":"Vascul Pharmacol"},{"issue":"3","key":"1761_CR88","doi-asserted-by":"publisher","first-page":"416","DOI":"10.2337\/dc17-1144","volume":"42","author":"N Laiteerapong","year":"2019","unstructured":"Laiteerapong N, Ham SA, Gao Y, et al. The legacy effect in type\u00a02 diabetes: impact of early glycemic control on future complications (the diabetes & aging study). Diabetes Care. 2019;42(3):416\u201326.","journal-title":"Diabetes Care"},{"issue":"1","key":"1761_CR89","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/S2213-8587(13)70202-X","volume":"2","author":"A Aminian","year":"2014","unstructured":"Aminian A, Brethauer SA, Kashyap SR, Kirwan JP, Schauer PR. DiaRem score: external validation. Lancet Diabetes Endocrinol. 2014;2(1):12\u20133.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"1761_CR90","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1007\/s11695-018-3583-3","volume":"29","author":"D Dicker","year":"2019","unstructured":"Dicker D, Golan R, Aron-Wisnewsky J, et al. Prediction of long-term diabetes remission after RYGB, sleeve gastrectomy, and adjustable gastric banding using DiaRem and advanced-DiaRem scores. Obes Surg. 2019;29(3):796\u2013804.","journal-title":"Obes Surg"},{"issue":"3","key":"1761_CR91","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/dme.13532","volume":"35","author":"A Pucci","year":"2018","unstructured":"Pucci A, Tymoszuk U, Cheung WH, et al. Type\u00a02 diabetes remission 2\u00a0years post Roux-en-Y gastric bypass and sleeve gastrectomy: the role of the weight loss and comparison of DiaRem and DiaBetter scores. Diabet Med. 2018;35(3):360\u20137.","journal-title":"Diabet Med"},{"issue":"4","key":"1761_CR92","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1097\/SLA.0000000000002407","volume":"266","author":"A Aminian","year":"2017","unstructured":"Aminian A, Brethauer SA, Andalib A, et al. Individualized metabolic surgery score: procedure selection based on diabetes severity. Ann Surg. 2017;266(4):650\u20137.","journal-title":"Ann Surg"},{"issue":"5","key":"1761_CR93","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.soard.2018.01.027","volume":"14","author":"JC Chen","year":"2018","unstructured":"Chen JC, Hsu NY, Lee WJ, Chen SC, Ser KH, Lee YC. Prediction of type\u00a02 diabetes remission after metabolic surgery: a comparison of the individualized metabolic surgery score and the ABCD score. Surg Obes Relat Dis. 2018;14(5):640\u20135.","journal-title":"Surg Obes Relat Dis"},{"issue":"1","key":"1761_CR94","doi-asserted-by":"publisher","first-page":"92","DOI":"10.2337\/dc21-0714","volume":"45","author":"D Barthold","year":"2022","unstructured":"Barthold D, Brouwer E, Barton LJ, et al. Minimum threshold of bariatric surgical weight loss for initial diabetes remission. Diabetes Care. 2022;45(1):92\u20139.","journal-title":"Diabetes Care"},{"issue":"12","key":"1761_CR95","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.soard.2023.09.025","volume":"19","author":"K Hage","year":"2023","unstructured":"Hage K, Ikemiya K, Ghusn W, et al. Type\u00a02 diabetes remission after Roux-en-Y gastric bypass: a multicentered experience with long-term follow-up. Surg Obes Relat Dis. 2023;19(12):1339\u201345.","journal-title":"Surg Obes Relat Dis"},{"issue":"11","key":"1761_CR96","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11883-020-00883-3","volume":"22","author":"ON Ajala","year":"2020","unstructured":"Ajala ON, Everett BM. Targeting inflammation to reduce residual cardiovascular risk. Curr Atheroscler Rep. 2020;22(11):66.","journal-title":"Curr Atheroscler Rep"},{"issue":"2","key":"1761_CR97","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41576-021-00414-z","volume":"23","author":"RJF Loos","year":"2022","unstructured":"Loos RJF, Yeo GSH. The genetics of obesity: from discovery to biology. Nat Rev Genet. 2022;23(2):120\u201333.","journal-title":"Nat Rev Genet"},{"issue":"13","key":"1761_CR98","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1001\/jama.2017.18391","volume":"319","author":"AL Beam","year":"2018","unstructured":"Beam AL, Kohane IS. Big data and machine learning in health care. JAMA. 2018;319(13):1317.","journal-title":"JAMA"},{"issue":"8","key":"1761_CR99","doi-asserted-by":"publisher","DOI":"10.2196\/25612","volume":"9","author":"Y Cao","year":"2021","unstructured":"Cao Y, N\u00e4slund I, N\u00e4slund E, Ottosson J, Montgomery S, Stenberg E. Using a convolutional neural network to predict remission of diabetes after gastric bypass surgery: machine learning study from the Scandinavian obesity surgery register. JMIR Med Inform. 2021;9(8):e25612.","journal-title":"JMIR Med Inform"},{"issue":"1","key":"1761_CR100","doi-asserted-by":"publisher","first-page":"16035","DOI":"10.1038\/npjgenmed.2016.35","volume":"1","author":"HK Pedersen","year":"2016","unstructured":"Pedersen HK, Gudmundsdottir V, Pedersen MK, Brorsson C, Brunak S, Gupta R. Ranking factors involved in diabetes remission after bariatric surgery using machine-learning integrating clinical and genomic biomarkers. NPJ Genomic Med. 2016;1(1):16035.","journal-title":"NPJ Genomic Med"},{"issue":"6","key":"1761_CR101","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/s41591-023-02344-1","volume":"29","author":"L Gao","year":"2023","unstructured":"Gao L, Lee BW, Chawla M, et al. Tirzepatide versus insulin glargine as second-line or third-line therapy in type\u00a02 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial. Nat Med. 2023;29(6):1500\u201310.","journal-title":"Nat Med"},{"issue":"6","key":"1761_CR102","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1111\/dom.15566","volume":"26","author":"B Cariou","year":"2024","unstructured":"Cariou B, Linge J, Neeland IJ, et al. Effect of tirzepatide on body fat distribution pattern in people with type\u00a02 diabetes. Diabetes Obes Metab. 2024;26(6):2446\u201355.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"1761_CR103","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089\u201398.","journal-title":"N Engl J Med"},{"issue":"16","key":"1761_CR104","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361.","journal-title":"N Engl J Med"},{"issue":"11","key":"1761_CR105","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.118.037778","volume":"139","author":"D Fitchett","year":"2019","unstructured":"Fitchett D, Inzucchi SE, Cannon CP, et al. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial. Circulation. 2019;139(11):1384\u201395.","journal-title":"Circulation"},{"issue":"2","key":"1761_CR106","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","unstructured":"The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117\u201327.","journal-title":"N Engl J Med"},{"issue":"12","key":"1761_CR107","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069\u201384.","journal-title":"N Engl J Med"},{"key":"1761_CR108","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ahj.2023.09.007","volume":"267","author":"SJ Nicholls","year":"2024","unstructured":"Nicholls SJ, Bhatt DL, Buse JB, et al. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type\u00a02 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. Am Heart J. 2024;267:1\u201311.","journal-title":"Am Heart J"},{"issue":"8","key":"1761_CR109","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1001\/jama.2024.0318","volume":"331","author":"AP Courcoulas","year":"2024","unstructured":"Courcoulas AP, Patti ME, Hu B, et al. Long-term outcomes of medical management vs bariatric surgery in type\u00a02 diabetes. JAMA. 2024;331(8):654.","journal-title":"JAMA"},{"issue":"7","key":"1761_CR110","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.2337\/dc21-2441","volume":"45","author":"JP Kirwan","year":"2022","unstructured":"Kirwan JP, Courcoulas AP, Cummings DE, et al. Diabetes remission in the alliance of randomized trials of medicine versus metabolic surgery in type\u00a02 diabetes (ARMMS-T2D). Diabetes Care. 2022;45(7):1574\u201383.","journal-title":"Diabetes Care"},{"issue":"3","key":"1761_CR111","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1210\/clinem\/dgaa006","volume":"105","author":"AP Courcoulas","year":"2020","unstructured":"Courcoulas AP, Gallagher JW, Neiberg RH, et al. Bariatric surgery vs lifestyle intervention for diabetes treatment: 5-year outcomes from a randomized trial. J Clin Endocrinol Metab. 2020;105(3):866\u201376.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"1761_CR112","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1210\/jc.2015-1443","volume":"100","author":"SA Ding","year":"2015","unstructured":"Ding SA, Simonson DC, Wewalka M, et al. Adjustable gastric band surgery or medical management in patients with type\u00a02 diabetes: a randomized clinical trial. J Clin Endocrinol Metab. 2015;100(7):2546\u201356.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1761_CR113","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s00464-018-6443-2","volume":"33","author":"D Foschi","year":"2019","unstructured":"Foschi D, Sorrentino L, Tubazio I, et al. Ileal interposition coupled with duodenal diverted sleeve gastrectomy versus standard medical treatment in type\u00a02 diabetes mellitus obese patients: long-term results of a case\u2013control study. Surg Endosc. 2019;33(5):1553\u201363.","journal-title":"Surg Endosc"},{"issue":"7","key":"1761_CR114","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1001\/jamasurg.2014.514","volume":"149","author":"F Halperin","year":"2014","unstructured":"Halperin F, Ding SA, Simonson DC, et al. Roux-en-Y gastric bypass surgery or lifestyle with intensive medical management in patients with type\u00a02 diabetes: feasibility and 1-year results of a randomized clinical trial. JAMA Surg. 2014;149(7):716.","journal-title":"JAMA Surg"},{"issue":"4","key":"1761_CR115","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1097\/SLA.0000000000000919","volume":"260","author":"M Parikh","year":"2014","unstructured":"Parikh M, Chung M, Sheth S, et al. Randomized pilot trial of bariatric surgery versus intensive medical weight management on diabetes remission in type\u00a02 diabetic patients who do not meet NIH criteria for surgery and the role of soluble RAGE as a novel biomarker of success. Ann Surg. 2014;260(4):617\u201324.","journal-title":"Ann Surg"},{"issue":"2","key":"1761_CR116","doi-asserted-by":"publisher","first-page":"444","DOI":"10.2337\/dc21-1335","volume":"45","author":"K Sj\u00f6holm","year":"2022","unstructured":"Sj\u00f6holm K, Carlsson LMS, Svensson PA, et al. Association of bariatric surgery with cancer incidence in patients with obesity and diabetes: long-term results from the Swedish obese subjects study. Diabetes Care. 2022;45(2):444\u201350.","journal-title":"Diabetes Care"},{"issue":"1","key":"1761_CR117","doi-asserted-by":"publisher","first-page":"20","DOI":"10.2337\/dc12-0779","volume":"36","author":"JB Dixon","year":"2013","unstructured":"Dixon JB, Chuang LM, Chong K, et al. Predicting the glycemic response to gastric bypass surgery in patients with type\u00a02 diabetes. Diabetes Care. 2013;36(1):20\u20136.","journal-title":"Diabetes Care"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01761-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-025-01761-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01761-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T19:17:44Z","timestamp":1757186264000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-025-01761-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,13]]},"references-count":117,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1761"],"URL":"https:\/\/doi.org\/10.1007\/s13300-025-01761-4","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,13]]},"assertion":[{"value":"17 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors declare that they have no competing interests. Salvatore Corrao, Fabio Falcone, Luigi Mirarchi, Simona Amodeo and Luigi Calvo have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}